Trastuzumab: Is the new evidence revolutionary?

Journal of Cancer Research and Therapeutics

Volumn 2, Issue 3, 2006, Pages 144-146

  Munshi, Anusheel ^a   Singh, Pritanjali ^a   Jalali, Rakesh ^a  

^a TATA MEMORIAL HOSPITAL   (India)

Author keywords

Evidence; Revolutionary; Trastuzumab

Indexed keywords

EID: 33749172008     PISSN: 09731482     EISSN: 09731482     Source Type: Journal    
DOI: 10.4103/0973-1482.27592     Document Type: Article

References (12)

1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82.
2. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that over expresses HER2. N Engl J Med 2001;344:783-92.
3. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-84.
4. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-72.
5. Hortobagyi GN. Trastuzumab in the treatment of breast cancer. N Engl J Med 2005;353:1734-6.
6. Menard S, Calini P, Tomasic G, Pilotti S, Cascinelli N, Bufalino R, et al. Pathologic identification of two distinct breast carcinoma subsets with diverging clinical behaviors. Breast Cancer Res Treat 1999;55:169-77.
7. Pietras RJ, Pegram MD, Finn RS, Maneval DA, Slamon DJ. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER2 receptor and DNA-reactive drugs. Oncogene 1998;17:2235-49.
8. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomized trials. Lancet 2005;365:1687-717.
9. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719-26.
10. Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: An overview of the randomized trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 2000;355:1757-70.
11. Cuzick J, Stewart H, Rutqvist L, et al. Cause specific mortality in long term survivors of breast cancer who participated in trials of radiotherapy. J Clin Oncol 1994;12:447-53.
12. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: An overview of the randomized trials Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Lancet 2006;366:2087-106.